Introduction {#S1}
============

The inappropriate attribution of salience to what would normally be irrelevant or neutral stimuli is a robust feature of psychotic disorders and is linked to altered subcortical dopaminergic signaling.^[@R1],[@R2]^ While there are a number of animal models that attempt to describe the pathology and development of psychosis (eg, chronic phencyclidine models, prenatal immune activation models (for review, see ref.^[@R3]^), a particularly influential model proposes that psychosis develops when hippocampal dysfunction drives increased subcortical dopamine activity through descending projections to the striatum.^[@R4],[@R5]^ Neuroimaging studies of reward salience suggest that salience processing and associated neural hippocampal-striatal-midbrain responses are perturbed in both patients with psychosis^[@R6],[@R7]^ and individuals at clinical high risk (CHR) for psychosis,^[@R8]--[@R11]^ and that this is associated with positive symptoms.^[@R11]^ In this context, although novelty has been less investigated as a dimension of salience than reward in psychosis,^[@R12]^ preclinical evidence indicates that dopaminergic neurons in the midbrain code the salience of unexpected stimuli and respond to novel stimuli.^[@R13],[@R14]^ The first aim of the present study was to examine hippocampal-striatum-midbrain circuit activation and effective connectivity in CHR individuals. We assessed activation using functional magnetic resonance imaging (fMRI) in conjunction with a novelty salience paradigm based on a task that had previously elicited robust hippocampal-striatal-midbrain responses,^[@R15]^ and employed Dynamic Casual Modeling (DCM)^[@R16]^ to assess effective connectivity within this circuit.

While previous neuroimaging studies had reported altered activation and connectivity in a hippocampal-striatal-midbrain circuit during reward salience processing in CHR individuals,^[@R8],[@R11]^ the extent to which these findings are specific to the CHR subset who later develop psychosis has yet to be investigated. Our second aim was to address this issue by examining the relationship between activation and connectivity within this circuit and the subsequent onset of a psychotic disorder. We, therefore, followed up our CHR participants to determine their clinical outcome.

Our primary hypothesis was that during novelty salience processing, hippocampal-striatal-midbrain circuit activation would be attenuated^[@R6],[@R7],[@R11]^ in CHR individuals compared to healthy controls (HC). We also examined how pure novelty salience processing altered effective connectivity in this circuit. Our second prediction was that these alterations would be particularly evident in the CHR subgroup who subsequently developed psychosis.

Methods {#S2}
=======

Participants {#S3}
------------

A total of 116 participants were recruited into the study. Ethical approval was obtained from the National Health Service UK Research Ethics Committee, and all participants provided written informed consent.

CHR participants (*n* = 85) were recruited from 4 different clinical sites in England: OASIS (Outreach and Support in South London),^[@R17]^ part of the South London and Maudsley NHS Trust; CAMEO, part of the Cambridge and Peterborough NHS Trust; the West London Early Intervention Service; and the Coventry and Warwick Warwickshire Partnership NHS Trust. All participants underwent clinical assessments and MRI scanning at King's College London (KCL) by 2 trained researchers (CS and BQ). CHR signs and symptoms for inclusion were assessed with the Comprehensive Assessment of At-Risk Mental States (CAARMS).^[@R18]^ Exclusion criteria were past/present diagnosis of psychotic disorders, past/present/familiar history of neurological illness, substance abuse/dependence according to DSM-5 criteria^[@R19]^ or contraindication to scanning.

HC (*n* = 31) were recruited from the same geographical areas as CHR participants. None had a personal/familial history of psychiatric/neurological disorder or were using prescription medication as assessed via self-report. Additional exclusion criteria for all participants involved self-reporting illicit substance use in the week prior to scanning or alcohol use in the 24 hours prior to scanning.

Clinical Measures {#S4}
-----------------

On the day of the MRI scan, the following measures were collected at KCL by trained raters: psychopathology using the CAARMS,^[@R18]^ anxiety and depression symptoms using the Hamilton Anxiety and Depression Scales (HAM-A/HAM-D),^[@R20]^ Premorbid IQ was estimated with the National Adult Reading Test (NART).^[@R21]^ Handedness was assessed using the Annett Handedness Scale.^[@R22]^ Participants provided information on tobacco (cigarettes/day), alcohol (units/day), and cannabis use (0 = no use, 1 = experimental use, 2 = occasional use, 3 = moderate use, 4 = severe use).

Novelty Salience Task {#S5}
---------------------

All participants underwent fMRI scanning on a 3T GE scanner at KCL using an event-related novelty salience task adapted from Bunzeck and Duzel.^[@R15]^ Participants completed three 6-minute runs of a visual oddball paradigm ([figure 1A](#F1){ref-type="fig"}). In each of the 3 runs, there were 80 standards (same picture in 73% of trials), 10 target oddballs (same picture in 9% of trials, requiring a button press at each presentation), 10 neutral oddballs (same picture in 9% of trials), and 10 novel oddballs (a unique picture in 9% of trials representing a "pure novel stimulus" ^[@R15]^), yielding a total of 360 stimuli across the entire 18-minute experiment (240 standards, 30 target oddballs, 30 neutral oddballs, and 30 novel oddballs). All pictures depicted black-and-white outdoor scenes.

The target stimulus, used solely to assess engagement with the task as in the original study^[@R15]^ (there was no measure of accuracy during novelty processing), was presented at the start of the experimental session for 4.5 seconds. Participants were asked to press a button with their right index finger every time it appeared (30 presentations in total). During the experiment, pictures were presented for 500 ms followed by a white fixation cross on a gray background with an inter-stimulus interval of 2.7 seconds, jittered between −300 ms and +300 ms (uniformly distributed).

Clinical Follow-up {#S6}
------------------

The entire CHR sample was followed up subsequent to scanning to determine clinical outcome (transition/non-transition to psychosis). The mean interval between baseline and follow-up assessments was 59.7 months (SD = 15.4 mo). Transition to psychosis was determined using CAARMS Psychosis Threshold criteria^[@R18]^ and confirmed with the Structured Clinical Interview for Diagnosis,^[@R19]^ administered by a psychiatrist trained in its use.

Image Acquisition and Preprocessing {#S7}
-----------------------------------

See [supplementary material](#SD1){ref-type="supplementary-material"} for details on fMRI acquisition and preprocessing.

Statistics {#S8}
----------

### Demographic, Clinical, and Behavioral Data {#S9}

Analyses of demographic data were performed in SPSS 24 ([http://www-01.ibm.com/software/uk/analytics/spss/](https://www.ibm.com/products/software)). The effect of group on these measures was examined using independent samples *t-*tests for parametric data and Chi-square tests for nonparametric data. To examine the relationship between fMRI activation and transition to psychosis, the CHR sample was divided into 2 groups at follow-up: a transition to psychosis group (CHR-T) and a non-transition to psychosis group (CHR-NT). Analysis of behavioral data were performed in SPSS 24 for reaction time (RT), target recognition and error rates using separate 2-sample *t*-tests: HC vs CHR and CHR-NT vs CHR-T. Significant effects are reported at *P* \< .05 with Bonferroni post hoc correction as appropriate (demographic data: age, sex, IQ, years of education, handedness, tobacco, alcohol, cannabis, antipsychotics, and antidepressant use---*P* \< .05/10 = *P* \< .005; clinical data: CAARMS positive, negative, total, GAF, HAM-A, and HAM-D---*P* \< .05/6 = *P* \< .008; behavior: targetness, errors, and RT---*P* \< .05/3 = *P* \< .017).

### fMRI Data Analysis {#S10}

Statistical analysis of the fMRI data was conducted using the general linear model in SPM12. Separate regressors of interest were specified for each trial type: Standard, Target, Neutral, and Novel. Realignment parameters (*x*, *y*, *z*, pitch, roll, yaw) were included in all first-level models as covariates of no interest to account for variance associated with head movement. All regressors were convolved with a canonical hemodynamic response function during the 500 ms in which trials were presented. One contrast image was generated for each participant to examine activation related to pure stimulus novelty by contrasting all novel oddball trials against neutral oddball trials^[@R15]^ and was then submitted to second-level analysis.

For between-group comparisons between HC and CHR participants, a 2-sample *t*-test was performed using the first-level novel \> neutral contrast images, covarying for age. We used an initial cluster defining threshold of *P* \< .001 uncorrected to then enforce a voxel-wise height threshold of family-wise error (FWE) *P* \< .05 after small volume correction (SVC) for region-of-interest (ROI) analyses,^[@R23],[@R24]^ using a pre-specified bilateral mask comprising the hippocampus, striatum, and midbrain. The striatum was chosen on the basis of its role in the aberrant salience hypothesis^[@R2]^ and previous fMRI studies documenting salience--related responses in this region.^[@R25]^ The hippocampus was chosen based on preclinical evidence for its central role in psychosis through the regulation of dopamine signaling,^[@R4]^ and prior work indicating a relationship between aberrant hippocampal activity and the CHR state.^[@R26],[@R27]^ The midbrain was chosen since novel stimuli are associated with fMRI activations in this region as shown by Bunzeck and Duzel's study using this task in healthy volunteers.^[@R15]^ The ROI mask was built using the WFU_Pitckatlas toolbox and comprised predefined anatomical masks of the striatum (caudate, pallidum, putamen) and the hippocampus from the automated anatomical labeling atlas, and a 6-mm sphere around the midbrain (ventral tegmental area/substantia nigra, VTA/SN) coordinates reported in the study with healthy volunteers^[@R15]^ (only right-sided as in Bunzeck & Duzel,^[@R15]^ *xyz*: 8, −20, −18; [figure 1B](#F1){ref-type="fig"}).

To investigate the relationship between functional activation in response to novelty and transition to psychosis, a 2-sample *t*-test was specified in SPM (CHR-NT vs CHR-T), adjusting for age. The same ROI mask and significance threshold as above were applied (*P*~FWE~ \< .05 after SVC). Potential confounding effects of substance use (alcohol, tobacco, cannabis) and levels of anxiety/depression (HAM-A/HAM-D) on the regions showing significant novelty-related group differences were examined with an additional ANCOVA in SPSS. Exploratory whole-brain voxel-wise analysis of fMRI data (comparing all CHR to HC subjects and CHR-NT to CHR-T subjects) is reported in the [supplementary material](#SD1){ref-type="supplementary-material"}.

Dynamic Casual Modeling {#S11}
-----------------------

### Volumes of Interest and Time-Series Extraction {#S12}

Based on preclinical evidence^[@R4],[@R5]^ and data from a previous study of the task in healthy volunteers,^[@R15]^ we used DCM12 in SPM12 to compute effective connectivity within a circuit comprising the hippocampus, the striatum and the midbrain ([figure 3A](#F3){ref-type="fig"}). The volumes of interest (VOIs) for these regions were defined using the maximally activated coordinates in the second-level fMRI analysis within our masked regions ([figure 1B](#F1){ref-type="fig"}), following published rules for the application of DCM.^[@R28]^ The VOI for the hippocampus was extracted from the group-level fMRI difference between CHR vs HCs (*xyz*: 38 −16 −14). As there was no significant group-level difference in either the striatum or midbrain, we used the coordinates of the task effect of novel \> neutral across all participants with an 8-mm sphere for each region, allowing the center of the sphere to move to the nearest suprathreshold voxel (*xyz*: striatum, 28 20 −2; VTA/SN, 14 −24 −16; *P~UNC~* \< .05).

### Group Comparisons With Parametric Empirical Bayes (PEB) {#S13}

PEB, included in SPM12, allows evaluating group effects and between-subjects variability on DCM parameters (HC vs CHR; CHR-NT vs CHR-T). PEB for DCM is performed by comparing the posterior density of any (reduced) model in terms of the posterior of its parent or full model. The first step is to estimate a full model (ie, with every connection switched "on") for every subject. Then, a nested model is constructed (ie, with certain conditions switched "off"), which allows the expression of the posterior density of any (reduced) model in terms of the posterior of its parent or full model. This process affords an efficient way to evaluate posterior densities under empirical priors. It is then possible to apply Bayesian model reduction to the posterior densities over the second-level parameters to find out where between-subject effects are expressed.^[@R29]^ Results are given by the group effect on the Posterior Probabilities (*P*) and the Bayesian Confidence Interval. Group differences were thresholded with a *P* \> .5 obtained as recommended by DCM's developers ([https://arxiv.org/pdf/1902.10604.pdf](https://arxiv.org/ftp/arxiv/papers/1902/1902.10604.pdf)) and following Kass & Raftery.^[@R30]^ Although comparing Bayes Factor to *P*-values is not straightforward, it could be argued that it is equivalent to *P* \< 0.05.^[@R31]^ The present study examined how the connections between the anterior hippocampus, ventral striatum and VTA/SN were modulated by stimulus novelty (novel \> neutral oddball trials) by generating a second model space which included a full model, to then create 4 different models with each connection switched "off" (nested models; [figure 3A](#F3){ref-type="fig"}). Group differences were then verified by comparing the evidence between the full model and the nested model. Group variables were de-meaned before being entered in the PEB model, to account for the different sample sizes of our study groups. Age was included as a covariate on all PEB analyses.

Additional exploratory analyses within the CHR group and its subgroups according to transition status were conducted to examine potential associations between severity of positive prodromal symptoms and fMRI response to novelty/DCM connectivity strengths ([supplementary eFigure 1](#SD1){ref-type="supplementary-material"}).

Results {#S14}
=======

Demographic and Clinical Data {#S15}
-----------------------------

Nine CHR participants were excluded from the final analyses due to incomplete fMRI data (*n* = 3), or excessive movement (*n* = 6). The analyzed sample thus comprised 76 CHR participants and 31 HCs. Detailed examination of potential movement confounds is reported in [supplementary eTable 1 and eFigure 2](#SD1){ref-type="supplementary-material"}.

All of the CHR participants met the CAARMS Attenuated Psychotic Symptoms criteria.^[@R32]^ A minority additionally fulfilled the BLIPS (*n* = 5) or schizotypal personality disorder/familial risk criteria (*n* = 2). At the time of scanning, most (67/76; 88%) CHR participants were naïve to antipsychotic medication. The remainder were taking low doses of antipsychotics (\<1.5 mg haloperidol equivalents per day). The majority of CHR participants were also anti-depressant free at the time of scanning (48/76; 63%).

The HC and CHR groups did not differ significantly in gender, handedness, estimated IQ, years of education, alcohol, or cannabis use. However, the CHR group was younger and smoked more tobacco. As would be expected, they showed higher levels of anxiety and depressive symptoms (HAM-A/HAM-D scores) and had lower levels of overall functioning compared to HCs (GAF score; [table 1](#T1){ref-type="table"}).

Thirteen of the CHR participants (17%) developed a psychotic disorder within the follow-up period of 59.7 months (CHR-T), while 63 participants did not (CHR-NT). There were no significant differences in demographic or clinical variables at baseline between these groups ([table 1](#T1){ref-type="table"}).

Behavioral Data {#S16}
---------------

The groups did not differ in their engagement with the fMRI task (mean RT or recognition of target stimuli; [supplementary eTable 2](#SD1){ref-type="supplementary-material"}).

fMRI Data {#S17}
---------

### Effect of Task {#S18}

Across groups, pure stimulus novelty was associated with activation in the anterior hippocampus, ventral striatum and midbrain bilaterally (*P*~FWE~ \< .05 after SVC; [table 2](#T2){ref-type="table"}, [figure 2A](#F2){ref-type="fig"}).

### Group Differences: All CHRs vs HCs {#S19}

In CHR participants, relative to HC, pure stimulus novelty (novel \> neutral oddball trial) was associated with significantly less activation in the anterior portion of the right hippocampus than in HCs (*P*~FWE~ = .041; *xyz* = 38 −16 −14; *Z* = 3.42, Hedges' *g* = 0.543; [figures 2B and C](#F2){ref-type="fig"}). There were no areas where CHR participants showed greater activation than HC. These findings remained unchanged after adding sex as additional covariate of no interest in the analysis (HC \> CHR: right hippocampus, *P*~FWE~ = .033; *xyz* = 38 −16 −14; *Z* = 3.49, Hedges' *g* = 0.544; CHR \> HC no suprathreshold voxels).

Because resting-state neuroimaging studies in CHR groups have reported increased hippocampal perfusion/metabolism,^[@R26],[@R27],[@R33],[@R34]^ we tested whether the reduced activation of the right anterior hippocampus in CHR relative to HC during pure stimulus novelty reflected an increased response to the neutral comparator stimuli that fMRI studies traditionally use.^[@R35]^ This supplementary analysis involved the contrast of neutral oddballs vs standards, reflecting activation related to unexpected, as opposed to novel stimuli, and revealed an increased hippocampal response in CHR relative to HC at a lenient threshold (*P* = .004 uncorrected, *xyz* = 36 −24 −16; k~*E*~ = 20; *Z* = 2.66; Hedges' *g* = 0.186; [figure 1](#F1){ref-type="fig"}).

### Group Differences: Transition to Psychosis {#S20}

There were no significant differences in activation between the CHR-T subgroup and either the CHR-NT subgroup or HCs. However, as in the total CHR sample, a lower right anterior hippocampal response to novel \> neutral stimuli was evident when CHR-NT were compared with HC (*P*~FWE~ = .018; *xyz* = 38 −16 −14; *Z* = 3.68, Hedges' *g* = 0.626). These findings remained unchanged after additionally adjusting the analysis for sex (HC \> CHR-NT: right hippocampus, *P*~FWE~ = 0.013; *xyz* = 38 −16 −14; *Z* = 3.76, Hedges' *g* = 0.488; HC \<\> CHR-T or CHR-NT \<\> CHR-T: no suprathreshold voxels). Clinical follow-up information (transition/non-transition) was not available for 6 of the 76 CHR individuals; repeating the transition analysis with these 6 individuals excluded from the CHR-NT group did not change the results (HC \> CHR-NT: right hippocampus, *P*~FWE~ = .019; *xyz* = 38 −16 −14; *Z* = 3.64, Hedges' *g* = 0.621; HC \<\> CHR-T or CHR-NT \<\> CHR-T: no suprathreshold voxels).

### Analysis of Potential Confounders {#S21}

A secondary analysis assessed the potentially confounding effects of substance use (alcohol, cigarettes, and cannabis) and levels of anxiety/depression (HAM-A/HAM-D) on the group difference in right anterior hippocampus activation. The group effect remained significant (*F*~1,80~ = 5.486, *P* = .022, Hedges' *g* = 0.742; [supplementaty eTable 3](#SD1){ref-type="supplementary-material"}). We also examined whether antipsychotic medication could have affected the results by repeating the analysis after the 9 CHR participants who were receiving antipsychotics had been excluded from the SPM design. Again, the group difference in the right anterior hippocampus remained significant (*P*~FWE~ = .042; *xyz* = 38, −18 −14; *Z* = 3.43, Hedges' *g* = 0.591). Finally, comparing CHR participants with (*n* = 28) vs CHR participants without (*n* = 48) antidepressants showed no suprathreshold effects at *P*~FWE~ \< .05.

Exploratory whole-brain fMRI results (comparing all CHR with HC subjects and CHR-NT with CHR-NT subjects) are reported in the [supplementary eTable 4 and eFigure 3](#SD1){ref-type="supplementary-material"}.

### Effective Connectivity: All CHRs vs HCs {#S22}

For the comparison of HC vs CHR groups, PEB revealed group differences in the modulatory effect of pure stimulus novelty on hippocampal-striatal-midbrain connections. The CHR group showed relatively reduced connectivity from VTA/SN to striatum (*P* = .52), but greater connectivity from hippocampus to striatum (*P* = .64) and from VTA/SN to hippocampus (*P* = .68; [figure 3B](#F3){ref-type="fig"}). These findings remained largely unchanged after additionally adjusting the analysis for sex (VTA/SN to hippocampus *P* = .74; hippocampus to striatum *P* = .63; although VTA/SN to striatum *P* = .47).

### Effective Connectivity: Transition to Psychosis {#S23}

Comparison of the CHR participants who subsequently developed psychosis and those who did not by PEB analysis also revealed a group difference: the CHR-T subgroup showed reduced connectivity from VTA/SN to striatum compared to the CHR-NT subgroup (*P* = .51; [figure 3C](#F3){ref-type="fig"}). This finding remained unchanged after additionally adjusting the analysis for sex (*P* = .53). Repeating this analysis excluding the 6 individuals for which follow-up clinical information was not available revealed that the reduced connectivity in CHR-T individuals from VTA/SN to striatum remained significant (*P* = .71), and a further connectivity decrease was observed for the backward connection from the striatum to the VTA/SN (*P* = .75; [supplementary eFigure 4](#SD1){ref-type="supplementary-material"}).

Discussion {#S24}
==========

Our first major finding was that participants at CHR for psychosis showed an altered anterior hippocampal response during pure stimulus novelty processing, suggesting that salience dysregulation is not only present in patients with psychosis, but is also evident before its onset. The result was not attributable to effects of age, treatment with antipsychotic or antidepressant medication, substance use, anxiety/depression symptoms, or differential behavioral engagement with the fMRI task. Complementary whole-brain analysis showed no significant between-group differences (as shown in the [supplementary material](#SD1){ref-type="supplementary-material"}), suggesting that during "pure stimulus novelty" processing, regions outside our a priori hippocampal-striatal-midbrain mask would not be differentially engaged by CHR individuals. The second major finding came from applying a circuit-based approach to examine functional coupling within a hippocampus--striatal--midbrain circuit during salience processing. CHR subjects showed significantly reduced effective connectivity from the midbrain to the striatum compared to controls, but greater connectivity from the hippocampus to the striatum and from the midbrain to the hippocampus. The reduction in midbrain-striatal connectivity in the whole sample was also evident in the subgroup who later became psychotic compared to the subgroup who did not. Overall, the results support previous reports that altered salience-related response in the hippocampus is associated with psychosis risk,^[@R8],[@R11]^ and suggest that the subsequent development of psychosis may rather be based on circuit-based connectivity disruptions.

According to a well-validated neurodevelopmental animal model, the methylazoxymethanol acetate (MAM) model, increased tonic activity of the ventral/anterior hippocampus leads the ventral striatum to disinhibit the midbrain via inhibition of the ventral pallidum, which increases the number of spontaneously active midbrain dopamine neurons.^[@R4],[@R36]^ Human imaging evidence has been largely consistent with this model.^[@R37]^ Resting cerebral blood volume (CBV) or flow (CBF) is elevated in the anterior hippocampus of patients with schizophrenia^[@R33],[@R34],[@R38],[@R39]^ and CHR individuals.^[@R26],[@R27],[@R34]^ Higher levels of CBV/CBF are positively associated with psychotic symptoms in CHR subjects^[@R33]^ and with subclinical psychotic-like experiences in schizotypal individuals.^[@R40]^ Furthermore, CHR subjects show elevated striatal dopamine function,^[@R41],[@R42]^ an association between striatal dopamine function and reduced hippocampal activation during a memory task,^[@R43]^ and altered hippocampal glutamate levels.^[@R44],[@R45]^ In turn, altered hippocampal glutamate levels have been related to abnormal hippocampal activation during a memory task in CHR.^[@R46]^ Our findings extend this literature by showing that hippocampal dysregulation is also evident when CHR individuals process novelty salience.

An important consideration in the interpretation of fMRI data is that increases and decreases in BOLD response depend on (1) the direction of the change in regional brain activity relative to the baseline for both the control and the task condition, (2) the way in which the control condition and the condition of interest are compared, and (3) comparing groups which may have different baseline states.^[@R35],[@R47]^ Our novelty salience paradigm was adapted from that employed by Bunzeck and Duzel,^[@R15]^ showing that the VTA/SN preferentially responds to stimulus novelty over other forms of stimulus salience. The contrast between novel and neutral oddballs allowed quantification of neural response to what the authors called "pure stimulus novelty," as opposed to rareness/deviance per se.^[@R15]^ Our results suggest that the reduced response to pure stimulus novelty in the right anterior hippocampus in CHR individuals may be driven by increased response to the control condition comprising neutral stimuli (albeit at an uncorrected level).

In terms of effective connectivity within this circuit, relative to controls, CHR subjects showed greater modulation by pure stimulus novelty in the connection from hippocampus to striatum and from midbrain to hippocampus. While this analysis also indicated reduced modulation of connectivity from midbrain to striatum in CHR individuals, this effect was no longer significant once sex was adjusted for in the analysis, suggesting a potential relationship between midbrain-striatal connectivity and sex in the CHR state which merits further research. Overall, these findings suggest that, in CHR subjects, afferent and efferent connectivity of the hippocampus were increased, consistent with disrupted interactions within a hippocampal-striatal-midbrain circuit being associated with increased risk for psychosis. This pattern of dysconnectivity would be in line with the maximal tonic activation of dopamine neuron firing hypothesized to occur in psychosis, thought to obscure salience-driven increases in population activity of mesostriatal dopamine neurons,^[@R36]^ leading to all stimuli being inappropriately registered as salient. This could account for the increased response to non-novel stimuli, and the attenuation of the hippocampal response to salient stimuli, observed in the CHR group.

Although the later onset of psychosis in CHR subjects was not associated with significant differences in hippocampal activation, this subgroup showed reduced modulation by pure stimulus novelty of the effective connectivity from midbrain to striatum compared to CHR subjects who did not become psychotic. As a similar alteration in midbrain-striatal connectivity was also evident in the total CHR sample relative to controls (above), this suggests that among the changes in connectivity seen in the CHR sample, alterations in communication from midbrain to striatum may be particularly relevant to the subsequent onset of psychosis. This would be consistent with PET studies in CHR subjects showing elevated midbrain and striatal dopamine function linked to later transition to psychosis.^[@R42],[@R43]^ An alternative explanation relates to a "ceiling effect" for hippocampal activity and subcortical connectivity in dopamine-related regions; the lower hippocampal response to novel vs non-novel stimuli could reflect a reduced signal-to-noise ratio in the comparison between these 2 conditions in CHR individuals, supported by the (uncorrected) hyper-responsivity to the neutral comparator condition. This notion is consistent with previous findings on emotional salience in CHR groups that lower responses to emotional stimuli are driven by increased responses to the neutral, nonemotional condition,^[@R48]--[@R52]^ and by reports of increased resting hippocampal perfusion in CHR.^[@R26],[@R27],[@R33],[@R34]^ Taken together, these results suggest that increased baseline activity/tonic dopamine signaling within this circuitry may render CHR/CHR-T individuals less able to "effectively" distinguish between novel (salient) and non-novel (non-salient) stimuli.

Despite studying a relatively large sample of CHR subjects, the number in the CHR-T subgroup was small; the findings in this subgroup should, therefore, be interpreted with caution, and warrant replication in larger samples. Previous imaging studies of salience processing in CHR individuals relative to HCs have found significant differences in activation of the hippocampal-striatal-midbrain circuit in the context of reward/motivational salience,^[@R8],[@R11]^ but not novelty or emotional salience. A possible explanation for this discrepancy might relate to modest sample sizes in previous studies, as we included a relatively large CHR sample (*n* = 76). Additional sources for discrepancies might relate to the use of different salience task paradigms, tapping on different dimensions of salience processing. More specifically, Roiser et al^[@R11]^ used the Salience Attribution Task (SAT), a monetary reward task measuring adaptive and aberrant motivational salience. In contrast, Winton-Brown et al^[@R8]^ used the Salience Integration Task (SIT), a monetary incentive delay task in which conditions were manipulated to examine reward (monetary), novelty (with half of the trials as pre-familiarized and the other half as novel), and aversion (with half of the pictures as emotionally aversive). Given that salience is a multifaceted construct,^[@R12]^ and that novelty salience had not been studied in relation to transition to psychosis, we used a task paradigm known to robustly isolate the specific processing of novelty.^[@R15]^ In terms of findings, Roiser et al focused on the dorsolateral prefrontal cortex, hippocampus, and midbrain, and found that the magnitude of aberrant motivational salience attribution was positively correlated with ventral striatal responses to non-salient cue features.^[@R11]^ Winton-Brown et al focused on the hippocampus, striatum, and midbrain, and found significant group differences with CHR subjects showing greater activation than HC to reward-predicting stimuli in the ventral pallidum and in the midbrain/hippocampus, while they did not observe any significant effects for novelty or emotional salience.^[@R8]^ In the present study, using a specific "pure stimulus novelty" salience task, we observed a significant difference in hippocampal responsivity between HC and CHR individuals. Finally, Roiser et al^[@R11]^ had shown an abnormal association between hippocampal response to motivational salience and dopamine synthesis capacity in a smaller sample of CHR individuals. Given that the hippocampus is central to the processing of novelty salience,^[@R53]^ it would be interesting to determine whether the hippocampal alteration we detected during novelty processing is also abnormally associated with dopamine synthesis capacity in CHR individuals.

In summary, the data from the present study indicate both perturbed hippocampal activation and hippocampal-striatal-midbrain effective connectivity in the context of novelty salience in people at CHR for psychosis, and that the later onset of psychosis is associated with alterations in midbrain-striatal connectivity. These findings are consistent with data from preclinical models of psychosis implicating alterations in a hippocampal--striatal-midbrain circuit in the development of psychosis.

Supplementary Material {#SM}
======================

Supplementary material is available at *Schizophrenia Bulletin* online.
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![(A) Task paradigm. (B) Region-of-interest mask used for small volume correction on the fMRI analysis, including the hippocampus, striatum, and midbrain. L = left hemisphere; R = right hemisphere.](EMS84625-f001){#F1}

![(A) Novel \> Neutral oddball trials across groups and (B) Between-group clinical high-risk (CHR) vs healthy control (HC) results in right hippocampus for the contrasts of novel \> neutral oddballs with activation superimposed on a standard T1 template. (C) Boxplots show mean hippocampal activation in each group for novel \> neutral (pure stimulus novelty) and neutral \> standard (stimulus rareness/deviance). L = left hemisphere; R = right hemisphere.](EMS84625-f002){#F2}

![(A) DCM model. (B) Group effects on PEB models between HC and CHR. (C) Group effects on PEB models between CHR-NT and CHR-T. Gray bars show posterior probabilities for model evidence. Bars represent the Bayesian 95% confidence interval.](EMS84625-f003){#F3}

###### Demographic and Questionnaire Data

  Measure                                                        HC (*n* = 31)     CHR (*n* = 76)   *g* or *V*   *P*          CHR-NT (*n* = 63)   CHR-T (*n* = 13)   *g* or *V*   *P*
  -------------------------------------------------------------- ----------------- ---------------- ------------ ------------ ------------------- ------------------ ------------ ------
  Age (y)                                                          25.0 (4.1)      22.46 (3.6)      0.677          **.003**     22.7 (3.8)          21.9 (2.6)       0.220        .488
  Gender (male/female)                                             15/16             42/34          0.063          .518         36/27                  6/7           0.083        .468
  NART IQ                                                        104.9 (13.7)      103.5 (14.6)     0.097          .669       103.6 (15.6)        103.1 (8.2)        0.034        .878
  Years of education                                               15.8 (3.5)        14.6 (2.2)     0.455          .071         14.6 (2.2)          14.5 (2.5)       0.044        .907
  CAARMS                                                                                                                                                                          
      Positive score                                                     -           10.1 (4.1)     \-                            9.7 (3.9)         11.8 (4.7)       0.520        .102
      Negative score                                                     -             5.1 (4.1)    \-                            5.1 (4.1)           4.8 (4.3)      0.073        .785
      Total score                                                        -           42.3 (22.4)    \-                          42.1 (21.9)         43.2 (25.5)      0.050        .873
  GAF score                                                        92.9 (5.0)        58.0 (9.5)     4.124        **\<.001**     58.5 (9.7)          55.3 (8.5)       0.336        .272
  HAM-A score                                                        3.4 (4.2)       18.4 (11.2)    1.542        **\<.001**     17.5 (10.4)         22.8 (14.2)      0.477        .173
  HAM-D score                                                        1.7 (3.5)       17.6 (11.1)    1.662        **\<.001**     17.0 (11.1)         20.3 (11.2)      0.297        .396
  Tobacco (cigarettes/d)                                             1.9 (3.4)         6.3 (9.0)    0.563          **.001**       7.2 (9.6)           2.1 (3.6)      0.573        .074
  Alcohol (units/d)                                                  1.7 (2.2)         1.6 (3.4)    0.032          .964           1.8 (3.6)           0.9 (0.7)      0.272        .426
  Cannabis (median \[range\])^[a](#TFN2){ref-type="table-fn"}^   0 \[0--3\]        0 \[0--4\]       0.146          .703       0 \[0--4\]          0 \[0--4\]         0.147        .811
  Antipsychotic medication (*n*)                                         -                9 (12%)   \-             -                 8 (13%)             1 (8%)      0.058        .611
  Antidepressant medication (*n*)                                       1 (3.2%)        28 (37%)    0.343        **\<.001**        25 (40%)              3 (23%)     0.130        .258
  Right-handed (*n*)                                                  26 (90%)          64 (85%)    0.187          .162            52 (83%)            12 (92%)      0.090        .434

*Note*: CAARMS, Comprehensive Assessment for the At-Risk Mental State; CHR, clinical high-risk; CHR-NT, clinical high-risk non-transition; CHR-T, clinical high-risk transition; GAF, Global Assessment of Functioning scale; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; HC, healthy controls; NART, National Adult Reading Test. *g* or *V*, Hedges' *g* or Cramer's *V*. Statistically significant results (after correction as described in the [Statistics](#S8){ref-type="sec"} section) are shown in bold text.

0 = never, 1 = experimental use, 2 = occasional use, 3 = moderate use, 4 = severe use.

###### Random Effects Analysis for Novel Oddballs vs Neutral Oddballs Across and Within Groups in the Hippocampal-Striatal-Midbrain Region-of-Interest

                                        MNI Coordinates                                       
  ------------------------------------- ----------------- ------- ------- ----- ------ ------ ---------
  Across all participants (*n* = 107)                                                         
      R anterior hippocampus              32              −12     −14     568   5.52   5.16   \<0.001
      L hippocampus                     −26               −30       −6    560   4.77   4.53     0.001
      R midbrain                          12              −24     −16     50    4.37   4.18   \<0.001
      R ventral putamen                   28                20      −2    963   5.91   5.47   \<0.001
      R dorsal pallidum                   18                  4       6         4.25   4.07     0.008
      R ventral caudate                   14                  8       6         4.15   3.98     0.012
      L ventral putamen                 −26                 14      −4    540   4.28   4.10     0.008
  HC (*n* = 31)                                                                               
      R anterior hippocampus              32              −14     −14     542   4.89   4.62   \<0.001
      L hippocampus                     −22               −34       −6    552   3.96   3.82     0.011
      R midbrain                          14              −18     −14     5     3.22   3.13     0.014
      R ventral putamen                   32                  4     −8    42    3.77   3.64     0.019
  CHR (*n* = 76)                                                                              
      R hippocampus                       22              −32       −2    18    3.63   3.51     0.031
      R midbrain                          12              −24     −16     24    4.00   3.85     0.002
      R ventral putamen                   28                20      −2    247   5.57   5.20   \<0.001
      L ventral putamen                 −26                 14      −6    19    3.68   3.56     0.024
  CHR-NT (*n* = 63)                                                                           
      R midbrain                          12              −24     −16     17    3.59   3.48     0.005
      R ventral putamen                   28                20      −2    124   5.43   5.08   \<0.001
  CHR-T (*n* = 13)                                                                            
  No suprathreshold voxels                                                                    

*Note*: L, left; R, right. CHR, clinical high-risk; CHR-NT, clinical high-risk non-transition; CHR-T, clinical high-risk transition; HC, healthy controls.
